 Dulcy Wolverton
Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 12 | 2025 | 166 | 1.050 |
Why?
| | Breast Neoplasms | 16 | 2025 | 2456 | 0.610 |
Why?
| | Comprehension | 3 | 2025 | 180 | 0.400 |
Why?
| | Health Literacy | 2 | 2024 | 184 | 0.330 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 61 | 0.270 |
Why?
| | Communication | 2 | 2023 | 967 | 0.240 |
Why?
| | Internet | 2 | 2025 | 700 | 0.200 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 421 | 0.200 |
Why?
| | Patients | 1 | 2023 | 182 | 0.180 |
Why?
| | Image Enhancement | 2 | 2021 | 199 | 0.170 |
Why?
| | Radiology | 2 | 2021 | 175 | 0.160 |
Why?
| | Mastectomy | 2 | 2020 | 162 | 0.160 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 463 | 0.150 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 95 | 0.150 |
Why?
| | Contrast Media | 2 | 2021 | 488 | 0.150 |
Why?
| | Patient Education as Topic | 1 | 2024 | 780 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 5 | 2021 | 3869 | 0.140 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 466 | 0.140 |
Why?
| | Patient Care Management | 1 | 2017 | 56 | 0.130 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 75 | 0.130 |
Why?
| | Breast | 2 | 2021 | 159 | 0.090 |
Why?
| | Aged | 9 | 2025 | 25947 | 0.080 |
Why?
| | Middle Aged | 12 | 2025 | 35928 | 0.080 |
Why?
| | Breast Diseases | 2 | 2000 | 22 | 0.070 |
Why?
| | Receptors, Estrogen | 1 | 2011 | 457 | 0.070 |
Why?
| | Female | 17 | 2025 | 78376 | 0.070 |
Why?
| | Humans | 22 | 2025 | 144957 | 0.070 |
Why?
| | Adult | 9 | 2025 | 40506 | 0.060 |
Why?
| | Fibroadenoma | 1 | 2005 | 2 | 0.060 |
Why?
| | Phyllodes Tumor | 1 | 2005 | 2 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 10 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6053 | 0.060 |
Why?
| | Spectrum Analysis | 1 | 2005 | 93 | 0.060 |
Why?
| | Patient Portals | 1 | 2024 | 49 | 0.050 |
Why?
| | Genetic Carrier Screening | 1 | 2002 | 32 | 0.050 |
Why?
| | Patient Navigation | 1 | 2024 | 104 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2884 | 0.050 |
Why?
| | BRCA2 Protein | 1 | 2002 | 67 | 0.050 |
Why?
| | BRCA1 Protein | 1 | 2002 | 81 | 0.050 |
Why?
| | Germ-Line Mutation | 1 | 2002 | 175 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2025 | 901 | 0.040 |
Why?
| | Electronics | 1 | 2021 | 71 | 0.040 |
Why?
| | Specialization | 1 | 2002 | 136 | 0.040 |
Why?
| | Patient Participation | 1 | 2024 | 433 | 0.040 |
Why?
| | Medicine | 1 | 2002 | 125 | 0.040 |
Why?
| | Radiographic Image Enhancement | 1 | 2000 | 57 | 0.040 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1465 | 0.040 |
Why?
| | Medical Oncology | 1 | 2023 | 332 | 0.040 |
Why?
| | Educational Status | 1 | 2022 | 467 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.040 |
Why?
| | Family Practice | 1 | 2023 | 404 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1077 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2002 | 781 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2022 | 544 | 0.030 |
Why?
| | Health Personnel | 1 | 2023 | 748 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5965 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2017 | 309 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1177 | 0.030 |
Why?
| | Databases, Factual | 2 | 2018 | 1486 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1671 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1958 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 853 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 1996 | 122 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2021 | 11695 | 0.030 |
Why?
| | Medicare | 1 | 2020 | 887 | 0.030 |
Why?
| | Clinical Competence | 1 | 2002 | 1244 | 0.030 |
Why?
| | Calcinosis | 1 | 1996 | 234 | 0.030 |
Why?
| | Prognosis | 2 | 2017 | 4293 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2005 | 183 | 0.020 |
Why?
| | Software | 1 | 2018 | 692 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2006 | 1718 | 0.020 |
Why?
| | Mass Screening | 1 | 2000 | 1348 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2002 | 1495 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2005 | 8279 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2021 | 17101 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1268 | 0.020 |
Why?
| | ROC Curve | 2 | 2002 | 615 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2006 | 88 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 1990 | 0.020 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 65 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2006 | 117 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2005 | 26 | 0.010 |
Why?
| | Gadolinium DTPA | 1 | 2005 | 68 | 0.010 |
Why?
| | Lasers | 1 | 2005 | 132 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 14126 | 0.010 |
Why?
| | Radiography | 1 | 2006 | 845 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 7997 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 555 | 0.010 |
Why?
| | United States | 1 | 2020 | 15988 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 5417 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 2006 | 1322 | 0.010 |
Why?
| | Physical Examination | 1 | 2000 | 240 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3415 | 0.010 |
Why?
| | Inflammation | 1 | 2006 | 2880 | 0.010 |
Why?
| | Algorithms | 1 | 2002 | 1839 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2002 | 2365 | 0.010 |
Why?
| | Risk Factors | 1 | 2002 | 10792 | 0.000 |
Why?
| | Adolescent | 1 | 2005 | 22453 | 0.000 |
Why?
|
|
Wolverton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|